Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,447,919
  • Shares Outstanding, K 37,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,990 K
  • 36-Month Beta 3.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.23 +5.79%
on 05/22/17
75.49 -11.39%
on 04/25/17
-5.93 (-8.14%)
since 04/21/17
3-Month
60.52 +10.53%
on 02/24/17
75.49 -11.39%
on 04/25/17
+4.96 (+8.01%)
since 02/22/17
52-Week
26.55 +151.94%
on 06/27/16
75.49 -11.39%
on 04/25/17
+35.68 (+114.32%)
since 05/20/16

Most Recent Stories

More News
Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 66.89 (+2.06%)
Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update

--Advancing SAGE-217 into Part B open-label Phase 2 trial in Parkinson's disease based on initial activity signal

SAGE : 66.89 (+2.06%)
Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time.

SAGE : 66.89 (+2.06%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.37 (+0.85%)
CBAY : 3.91 (unch)
SAGE : 66.89 (+2.06%)
CBIO : 3.90 (-3.23%)
BNIKF : 0.1392 (+3.88%)
Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 66.89 (+2.06%)
Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the appointment...

SAGE : 66.89 (+2.06%)
5 Drug Stocks for Your Portfolio this World Health Day

With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

JNJ : 127.26 (+0.20%)
AGN : 219.52 (+0.18%)
SAGE : 66.89 (+2.06%)
ALKS : 58.32 (+0.71%)
VTGN : 1.99 (+1.02%)
First Week of November 17th Options Trading For Sage Therapeutics (SAGE)

Investors in Sage Therapeutics Inc saw new options become available this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

SAGE : 66.89 (+2.06%)
Pershing Gold to Present at 2017 European Gold Forum

Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers...

PGLC.TO : 3.93 (-1.75%)
SAGE : 66.89 (+2.06%)
PGLC : 2.88 (-0.69%)
Pershing Gold to Present at 2017 European Gold Forum

Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers...

PGLC.TO : 3.93 (-1.75%)
SAGE : 66.89 (+2.06%)
PGLC : 2.88 (-0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Support & Resistance

2nd Resistance Point 69.48
1st Resistance Point 68.18
Last Price 66.89
1st Support Level 64.41
2nd Support Level 61.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.